SANTHERA PHARMACEUTICALS HOLDING AG (CHF.IMC) — HY 2025 Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the SANTHERA PHARMACEUTICALS HALF YEAR RESULTS INVESTOR PRESENTATION. Questions are encouraged. They can be submitted at any time via the Q and A tab that's just situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and will provide shared responses where it's appropriate to do so. Before we begin, we would just like to submit the following poll. If you could give that your kind attention, I'm sure the company would be most grateful. And I would now like to hand you over to the team from SANTHERA PHARMACEUTICALS, Catherine Shabir. Good afternoon. Good afternoon, everyone, and welcome again to the interim results for the six months ending the 06/30/2025. Giving the presentation today is myself, Katherine Issaid, the CFO, as well as our chief medical officer, doctor Shabir Hassan. Unfortunately, our CEO, Dario Eklund, cannot be with us today as he's actually had a recent operation on his shoulder, but he will be back with us shortly. As was said in the introduction, there will be an opportunity to ask questions at the end of the presentation, so please add these into the box as we go along. To start with, as always, we have disclaimer. Please feel free to read this at your leisure. While I appreciate this is a results call, we thought it's worthwhile spending a bit of time going through who SANTHERA is and what we do and also a reminder about the DMD market. So I will start off with this small snapshot of the company. So we are a Swiss listed company listed on six with our global headquarters in Basel wi...